Continuous infusion vs. bolus dosing: Implications for beta-lactam antibiotics

Minerva Anestesiologica

Volumn 78, Issue 1, 2012, Pages 94-104

  Abdul Aziz, Mohd Hafiz ^a   Staatz, C E ^b   Kirkpatrick, C M J ^c   Lipman, J ^b,d   Roberts, J A ^b,d  

^a INTERNATIONAL ISLAMIC UNIVERSITY MALAYSIA   (Malaysia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Infusion pumps; Monobactams; Pharmacokinetics; Pharmacology; Treatment outcome

Indexed keywords

BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CARBENICILLIN; CEFAMANDOLE; CEFAZOLIN; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; FLUCLOXACILLIN; GENTAMICIN; MEROPENEM; MONOBACTAM DERIVATIVE; OXACILLIN; PENICILLIN DERIVATIVE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TEMOCILLIN;

ABDOMINAL INFECTION; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; ARTIFICIAL VENTILATION; BACTERIAL ENDOCARDITIS; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; BOLUS INJECTION; CANCER PATIENT; CONTINUOUS INFUSION; CRITICALLY ILL PATIENT; CYSTIC FIBROSIS; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG PENETRATION; DRUG SAFETY; FEBRILE NEUTROPENIA; FEVER; GASTROINTESTINAL DISEASE; GRAM NEGATIVE INFECTION; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; LEUKOCYTE COUNT; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; PHARMACODYNAMICS; PNEUMONIA; PSEUDOMONAS INFECTION; SEPSIS; SEPTICEMIA; STEADY STATE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VENTILATOR ASSOCIATED PNEUMONIA;

ADULT; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BETA-LACTAMS; CHILD; CRITICAL CARE; CRITICAL ILLNESS; CYSTIC FIBROSIS; FEVER; HUMANS; INFUSIONS, INTRAVENOUS; LENGTH OF STAY; LEUKOCYTE COUNT; NEOPLASMS; RESPIRATION, ARTIFICIAL; TREATMENT OUTCOME;

EID: 84855832561     PISSN: 03759393     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Dellinger RP, Levy MM, Carlett JM, Bion J, Parker MM, Jaeschke R et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008;36:296-327.
2. Roberts JA, Lipman J. Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin Pharmacokinet 2006;45:755-73.
3. Pinder M, Bellomo R, Lipman J. Pharmacological principles of antibiotic prescription in the critically ill. Anaesth Intensive Care 2002;30:134-44.
4. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 2009;37:840-51.
5. Craig WA. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-10.
6. Mouton JW, den Hollander JG. Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 1994;38:931-6.
7. Turnidge JD. The pharmacodynamics of beta-lactams. Clin Infect Dis 1998;27:10-22.
8. Andes C. Treatment of Infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations. Clin Microbiol Infect 2005;11(S6):10-7.
9. Ulldemolins M, Roberts JA, Wallis SC, Rello J, Lipman J. Flucloxacillin dosing in critically ill patients with hypoalbuminaemia-special emphasis on unbound pharmacokinetics. J Antimicrob Chemother 2010;65:1771-8.
10. Roberts JA, Lipman J, Blot S, Rello J. Better outcomes through continuous infusion of time-dependant antibiotics to critically ill patients? Curr Opin Crit Care 2008;14:390-6.
11. Roberts JA, Roberts MS, Robertson TA, Dalley AJ, Lipman J. Piperacillin penetration into tissue of critically ill patients with sepsis-bolus versus continuous administration? Crit Care Med 2009;37:926-33.
12. Langgartner J, Vasold A, Gluck T, Reng M, Kees F. Pharmacokinetics of meropenem during intermittent and continuous intravenous application in patients treated by continuous renal replacement therapy. Intensive Care Med 2008;34:1091-6.
13. De Jongh R, Hens R, Basma V, Mouton JW, Tulkens PM, Carryn S. Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. J Antimicrob Chemother 2008;61:382-8.
14. Langgartner J, Lehn N, Gluck T, Herzig H, Kees F. Comparison of the pharmacokinetics of piperacillin and sulbactam during intermittent and continuous intravenous infusion. Chemotherapy 2007;53:370-7.
15. Georges B, Conil JM, Cougot P, Decun JF, Archambaud M, Seguin T et al. Cefepime in critically ill patients: continuous infusion vs. intermittent dosing regimen. Int J Clin Pharmacol Ther 2005;43:360-9.
16. Li C, Kuti JL, Nightingale CH, Mansfield DL, Dana A, Nicolau DP. Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection. J Antimicrob Chemother 2005;56:388-95.
17. Buck C, Bertram N, Ackermann T, Sauerbruch T, Derendorf H, Paar WD. Pharmacokinetics of piperacillin/tazobactam: intermittent dosing versus continuous infusion. Int J Antimicrob Agents 2005;25:62-7.
18. Buijk SL, Gyssens IC, Mouton JW, Van Vliet A, Verbrugh HA, Bruining HA. Pharmacokinetics of ceftazidime in serum and peritoneal exudates during continuous versus intermittent administration to patients with severe intra-abdominal infections. J Antimicrob Chemother 2002;49:121-8.
19. Hanes SD, Wood GC, Herring V, Croce MA, Fabian TC, Pritchard E, Boucher BA. Intermittent and continuous ceftazidime infusion for critically ill trauma patients. Am J Surg 2000;179:436-40.
20. Thalhammer F, Traunmuller F, El Menyawi I, Frass M, Hollenstein UM, Locker GJ et al. Continuous infusion versus intermittent administration of meropenem in critically ill patients. J Antimicrob Chemother 1999;43:523-7.
21. Benko AS, Cappelletty DM, Kruse JA, Rybak MJ. Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections. Antimicrob Agents Chemother 1996;40:691-5.
22. Roberts JA, Kirkpatrick CMJ, Roberts MS, Robertson TA, Dalley AJ, Lipman J. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction-intermittent bolus dosing vs. continuous administration? Monte-Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother 2009;64:142-50.
23. Adembri C, Ristori R, Chelazzi C, Arriguci S, Cassetta MI, De Gaudio AR et al. Cefazolin bolus and continuous administration for elective cardiac surgery: improved pharmacokinetic and pharmacodynamic parameters. J Thorac Cardiovasc Surg 2010;140:471-5.
24. Suffoletta TJ, Jennings HR, Oh JJ, Stephens D, Poe KL. Continuous versus intermittent infusion of prophylactic cefoxitin after colorectal surgery: a pilot study. Pharmacotherapy 2008;28:1133-9.
25. Buijk SE, Gyssens IC, Mouton JW, Metselaar HJ, Groenland TH, Verbrugh HA et al. Perioperative pharmacokinetics of cefotaxime in serum and bile during continuous and intermittent infusion in liver transplant patients. J Antimicrob Chemother 2004;54:199-205.
26. Riethmueller J, Junge S, Schroeter TW, Kuemmerer K, Franke P, Ballmann M et al. Continuous vs thrice-daily ceftazidime for elective intravenous antipseudomonal therapy in cystic fibrosis. Infection 2009;37:418-23.
27. Hubert D, Le Roux E, Lavrut T, Wallaert B, Scheid P, Manach D et al. Continuous versus intermittent infusions of ceftazidime for treating exacerbation of cystic fibrosis. Antimicrob Agents Chemother 2009;53:3650-6.
28. Kuti JL, Nightingale CH, Knauft RF, Nicolau DP. Pharmacokinetic properties and stability of continuous-infusion meropenem in adults with cystic fibrosis. Clin Ther 2004;26:493-501.
29. Rappaz I, Decosterd LA, Bille J, Pilet M, Belaz N, Roulet M. Continuous infusion of ceftazidime with a portable pump is as effective as thrice-a-day bolus in cystic fibrosis children. Eur J Pediatr 2000;159:919-25.
30. Permin H, Koch C, Hoiby N, Christensen HO, Moller AF, Moller S. Ceftazidime treatment in chronic Pseudomonas aeruginosa respiratory tract infection in cystic fibrosis. J Antimicrob Chemother 1983;12:313-23.
31. Vinks AA, Brimicombe RW, Heijerman HG, Bakker W. Continuous infusion of ceftazidime in cystic fibrosis patients during home treatment: clinical outcome, microbiology and pharmacokinetics. J Antimicrob Chemother 1997;40:125-33.
32. Dalle JH, Gnansounou M, Husson MO, Lambilliotte A, Mazingue F, Nelken B. Continuous infusion of ceftazidime in the empiric treatment of febrile neutropenic children with cancer. J Pediatr Hematol Onco 2002;24:714-6.
33. Egerer G, Goldschmidt H, Hensel M, Harter C, Schneeweiss A, Ehrhard I, Bastert G, Ho AD. Continuous infusion of ceftazidime for patients with breast cancer and multiple myeloma receiving high-dose chemotherapy and peripheral blood stem cell transplantation. Bone Marrow Transplant 2002;30:427-31.
34. Bodey GP, Ketchel SJ, Rodriguez V. A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients. Am J Med 1979;67:608-16.
35. Boselli E, Breilh D, Rimmele T, Guillaume C, Xuereb F, Saux MC et al. Alveolar concentrations of piperacillin/ tazobactam administered in continuous infusion to patients with ventilator-associated pneumonia. Crit Care Med 2008;36:1500-6.
36. Roberts JA, Paratz J, Paratz E, Krueger WA, Lipman J. Continuous infusion of beta-lactam antibiotics in severe infections: a review of its role. Int J Antimicrob Agents 2007;30:11-8.
37. Roberts JA, Boots R, Rickard CM, Thomas P, Quinn J, Roberts DM et al. Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care? A randomized controlled pilot study. J Antimicrob Chemother 2007;59:285-91.
38. Rafati MR, Rouini MR, Mojtahedzadeh M, Najafi A, Tavakoli H, Gholami K et al. Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients. Int J Antimicrob Agents 2006;28:122-7.
39. Lau WK, Mercer D, Itani KM, Nicolau DP, Kuti JL, Mansfield D et al. Randomized, open-label, comparative study of piperacillin/tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection. Antimicrob Agents Chemother 2006;50:3556-61.
40. Angus BJ, Smith MD, Suputtamongkol Y, Mattie H, Walsh AL, Wuthiekanun V et al. Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs. intermittent bolus injection in septicaemic melioidosis. Clin Pharmacol 2000;50:184-91.
41. Lorente L, Jimenez A, Martin MM, Iribarren JL, Jimenez JJ, Mora ML. Clinical cure of ventilator-associated pneumonia treated with piperacillin/tazobactam administered by continuous or intermittent infusion. Int J Antimicrob Agents 2009;33:464-8.
42. Lodise TP Jr, Lomaestro B, Drusano GL. Piperacillin/tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 2007;44:357-63.
43. Roberts JA, Webb S, Paterson D, Ho KM, Lipman J. A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics. Crit Care Med 2009;37:2071-8.
44. Hughes DW, Frei CR, Maxwell PR, Green K, Patterson JE, Crawford GE et al. Continuous versus intermittent infusion of oxacillin for treatment of infective endocarditis caused by Methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother 2009;53:2014-9.
45. Nicolau DP, McNabb J, Lacy MK, Quintiliani R, Nightingale CH. Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. Int J Antimicrob Agents 2001;17:497-504.
46. McNabb JJ, Nightingale CH, Quintiliani R, Nicolau DP. Cost-effectiveness of ceftazidime by continuous infusion versus intermittent infusion for nosocomial pneumonia. Pharmacotherapy 2001;21:549-55.
47. Van Zanten AR, Oudijk M, Nohlmans-Paulssen MK, van der Meer YG, Girbes AR, Polderman KH. Continuous vs. intermittent cefotaxime administration in patients with chronic obstructive pulmonary disease and respiratory tract infections: pharmacokinetics/pharmacodynamics, bacterial susceptibility and clinical efficacy. Br J Clin Pharmacol 2007;63:100-9.
48. Viaene E, Chanteux H, Servais H, Mingeot-Leclercq MP, Tulkens PM. Comparative stability studies of antipseudomonal β-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units). Antimicrob Agents Chemother 2002;46:2327-32.
49. Jaruratanasirikul S, Sriwiriyajan S. Comparison of the pharmacodynamics of meropenem in healthy volunteers following administration by intermittent infusion or bolus injection. J Antimicrob Chemother 2003;52:518-21.
50. Boselli E, Breilh D, Cannesson M, Xuereb F, Rimmele T, Chassard D et al. Steady-state plasma and intrapulmonary concentrations of piperacillin/tazobactam 4 g/0.5 g administered to critically ill patients with severe nosocomial pneumonia. Intensive Care Med 2004;30:976-9.